

Alexander J Szalai

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/784115/publications.pdf>

Version: 2024-02-01

98
papers

5,979
citations

57681

46
h-index

84171

75
g-index

98
all docs

98
docs citations

98
times ranked

7130
citing authors

#	ARTICLE	IF	CITATIONS
1	Therapeutic Lowering of C-Reactive Protein. <i>Frontiers in Immunology</i> , 2020, 11, 619564.	2.2	23
2	C-Reactive Protein Promotes the Expansion of Myeloid Derived Cells With Suppressor Functions. <i>Frontiers in Immunology</i> , 2019, 10, 2183.	2.2	27
3	Mice expressing the variant rs1143679 allele of ITGAM (CD11b) show impaired DC-mediated T cell proliferation. <i>Mammalian Genome</i> , 2019, 30, 245-259.	1.0	6
4	C-Reactive Protein Impairs Dendritic Cell Development, Maturation, and Function: Implications for Peripheral Tolerance. <i>Frontiers in Immunology</i> , 2018, 9, 372.	2.2	52
5	Hyposialylated IgG activates endothelial IgG receptor FcγRIIB to promote obesity-induced insulin resistance. <i>Journal of Clinical Investigation</i> , 2017, 128, 309-322.	3.9	82
6	C-reactive protein exacerbates renal ischemia-reperfusion injury: are myeloid-derived suppressor cells to blame?. <i>American Journal of Physiology - Renal Physiology</i> , 2016, 311, F176-F181.	1.3	22
7	C-reactive protein promotes acute kidney injury via Smad3-dependent inhibition of CDK2/cyclin E. <i>Kidney International</i> , 2016, 90, 610-626.	2.6	54
8	Human C-reactive protein impedes entry of leptin into the CNS and attenuates its physiological actions in the CNS. <i>Biochemical Journal</i> , 2016, 473, 1215-1224.	1.7	5
9	Hepatic but Not CNS-Expressed Human C-Reactive Protein Inhibits Experimental Autoimmune Encephalomyelitis in Transgenic Mice. <i>Autoimmune Diseases</i> , 2015, 2015, 1-8.	2.7	12
10	C-Reactive Protein Directly Suppresses Th1 Cell Differentiation and Alleviates Experimental Autoimmune Encephalomyelitis. <i>Journal of Immunology</i> , 2015, 194, 5243-5252.	0.4	44
11	Serum eotaxin-1 is increased in extremely-low-birth-weight infants with bronchopulmonary dysplasia or death. <i>Pediatric Research</i> , 2015, 78, 498-504.	1.1	17
12	The role of genetic variants in CRP in radiographic severity in African Americans with early and established rheumatoid arthritis. <i>Genes and Immunity</i> , 2015, 16, 446-451.	2.2	8
13	Effects of the Dietary n-3:n-6 Fatty Acid Ratio on Body Fat and Inflammation in Zebrafish (<i>Danio rerio</i>). <i>Comparative Medicine</i> , 2015, 65, 289-94.	0.4	13
14	Associations Between Abnormal Rod-Mediated Dark Adaptation and Health and Functioning in Older Adults With Normal Macular Health. , 2014, 55, 4776.		62
15	C-Reactive Protein and Arteriosclerosis. <i>Mediators of Inflammation</i> , 2014, 2014, 1-1.	1.4	6
16	C-reactive protein promotes acute kidney injury by impairing G1/S-dependent tubular epithelium cell regeneration. <i>Clinical Science</i> , 2014, 126, 645-659.	1.8	57
17	Inhibiting C-Reactive Protein for the Treatment of Cardiovascular Disease: Promising Evidence from Rodent Models. <i>Mediators of Inflammation</i> , 2014, 2014, 1-9.	1.4	31
18	C-reactive protein induces expression of tissue factor and plasminogen activator inhibitor-1 and promotes fibrin accumulation in vein grafts. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 1667-1677.	1.9	20

#	ARTICLE	IF	CITATIONS
19	Deletion of C-reactive protein ameliorates experimental cerebral malaria?. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2014, 108, 591-593.	0.7	3
20	Estrogen Effects on Vascular Inflammation Are Age Dependent. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 1477-1485.	1.1	57
21	Human Neutrophil Flow Chamber Adhesion Assay. Journal of Visualized Experiments, 2014, , .	0.2	10
22	C-reactive protein exacerbates renal ischemia-reperfusion injury. American Journal of Physiology - Renal Physiology, 2013, 304, F1358-F1365.	1.3	45
23	Multiple Lupus-Associated <i>ITGAM</i> Variants Alter Macrophage Functions on Neutrophils. Arthritis and Rheumatism, 2013, 65, 2907-2916.	6.7	47
24	A Selective Inhibitor of Human C-reactive Protein Translation Is Efficacious In Vitro and in C-reactive Protein Transgenic Mice and Humans. Molecular Therapy - Nucleic Acids, 2012, 1, e52.	2.3	40
25	Associations of C-Reactive Protein to Indices of Vascular Health and the Influence of Serum 25(OH)D Status in Healthy Adults. Journal of Nutrition and Metabolism, 2012, 2012, 1-6.	0.7	17
26	Pneumococcal Surface Protein A Inhibits Complement Deposition on the Pneumococcal Surface by Competing with the Binding of C-Reactive Protein to Cell-Surface Phosphocholine. Journal of Immunology, 2012, 189, 5327-5335.	0.4	86
27	Kidney Injury Accelerates Cystogenesis via Pathways Modulated by Heme Oxygenase and Complement. Journal of the American Society of Nephrology: JASN, 2012, 23, 1161-1171.	3.0	40
28	C-reactive protein promotes acute renal inflammation and fibrosis in unilateral ureteral obstructive nephropathy in mice. Laboratory Investigation, 2011, 91, 837-851.	1.7	61
29	C-reactive protein promotes diabetic kidney disease in a mouse model of type 1 diabetes. Diabetologia, 2011, 54, 2713-2723.	2.9	65
30	Collagen-induced arthritis is exacerbated in C-reactive protein-deficient mice. Arthritis and Rheumatism, 2011, 63, 2641-2650.	6.7	36
31	Inhibition of Experimental Autoimmune Encephalomyelitis in Human C-Reactive Protein Transgenic Mice Is FcRIIB Dependent. Autoimmune Diseases, 2011, 2011, 1-6.	2.7	14
32	An About-Face for C-Reactive Protein?. Clinical Chemistry, 2011, 57, 1351-1353.	1.5	2
33	Biomarkers of inflammation and hemostasis associated with left ventricular mass: The Multiethnic Study of Atherosclerosis (MESA). International Journal of Molecular Epidemiology and Genetics, 2011, 2, 391-400.	0.4	22
34	Response to C-Reactive Protein and Cardiovascular Disease: Differences Between Humans and Mice. Hypertension, 2010, 56, .	1.3	0
35	C-Reactive Protein-Mediated Vascular Injury Requires Complement. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 1189-1195.	1.1	40
36	Complement Receptor 1 Expression on Mouse Erythrocytes Mediates Clearance of <i>Streptococcus pneumoniae</i> by Immune Adherence. Infection and Immunity, 2010, 78, 3129-3135.	1.0	28

#	ARTICLE	IF	CITATIONS
37	C-Reactive Protein Promotes Cardiac Fibrosis and Inflammation in Angiotensin II-Induced Hypertensive Cardiac Disease. <i>Hypertension</i> , 2010, 55, 953-960.	1.3	98
38	Antibody to the Type 3 Capsule Facilitates Immune Adherence of Pneumococci to Erythrocytes and Augments Their Transfer to Macrophages. <i>Infection and Immunity</i> , 2009, 77, 464-471.	1.0	18
39	The role of C-reactive protein polymorphisms in inflammation and cardiovascular risk. <i>Current Atherosclerosis Reports</i> , 2009, 11, 124-130.	2.0	30
40	Exaggerated Neointima Formation in Human C-Reactive Protein Transgenic Mice Is IgG Fc Receptor Type I (Fc γ RI)-Dependent. <i>American Journal of Pathology</i> , 2008, 172, 22-30.	1.9	49
41	Neointimal formation is reduced after arterial injury in human crp transgenic mice. <i>Atherosclerosis</i> , 2008, 201, 85-91.	0.4	10
42	Impaired endothelial function in C-reactive protein overexpressing mice. <i>Atherosclerosis</i> , 2008, 201, 318-325.	0.4	69
43	Immune Opsonins Modulate BlyS/BAFF Release in a Receptor-Specific Fashion. <i>Journal of Immunology</i> , 2008, 181, 1012-1018.	0.4	23
44	Overexpression of innate immune response genes in a model of recessive polycystic kidney disease. <i>Kidney International</i> , 2008, 73, 63-76.	2.6	82
45	PspA and PspC Minimize Immune Adherence and Transfer of Pneumococci from Erythrocytes to Macrophages through Their Effects on Complement Activation. <i>Infection and Immunity</i> , 2007, 75, 5877-5885.	1.0	57
46	Complement in experimental autoimmune encephalomyelitis revisited: C3 is required for development of maximal disease. <i>Molecular Immunology</i> , 2007, 44, 3132-3136.	1.0	54
47	C-Reactive Protein Gene Polymorphisms, C-Reactive Protein Blood Levels, and Cardiovascular Disease Risk. <i>Journal of the American College of Cardiology</i> , 2007, 50, 1115-1122.	1.2	185
48	Genetic deficiency of C3 as well as CNS-targeted expression of the complement inhibitor sCrry ameliorates experimental autoimmune uveoretinitis. <i>Experimental Eye Research</i> , 2006, 82, 389-394.	1.2	53
49	Experimental autoimmune uveitis in the C57BL/6 mouse. <i>Experimental Eye Research</i> , 2006, 83, 229-230.	1.2	4
50	Complement in BuB/BnJ mice revisited: Serum C3 levels and complement opsonic activity are not elevated. <i>Molecular Immunology</i> , 2006, 43, 1722-1725.	1.0	19
51	Anti-Atherosclerotic Effect of Amlodipine, Alone and in Combination With Atorvastatin, in APOE*3-Leiden/hCRP Transgenic Mice. <i>Journal of Cardiovascular Pharmacology</i> , 2006, 47, 89-95.	0.8	21
52	Induction of leptin resistance through direct interaction of C-reactive protein with leptin. <i>Nature Medicine</i> , 2006, 12, 425-432.	15.2	294
53	Complement and demyelinating disease: No MAC needed?. <i>Brain Research Reviews</i> , 2006, 52, 58-68.	9.1	28
54	Requirement of the Fc receptor common β -chain for γ T cell-mediated promotion of murine experimental autoimmune encephalomyelitis. <i>European Journal of Immunology</i> , 2005, 35, 3487-3492.	1.6	17

#	ARTICLE	IF	CITATIONS
55	Murine complement C4 is not required for experimental autoimmune encephalomyelitis. <i>Glia</i> , 2005, 49, 158-160.	2.5	32
56	Single-nucleotide polymorphisms in the C-reactive protein (CRP) gene promoter that affect transcription factor binding, alter transcriptional activity, and associate with differences in baseline serum CRP level. <i>Journal of Molecular Medicine</i> , 2005, 83, 440-447.	1.7	146
57	Estrogen Treatment Abrogates Neointima Formation in Human C-Reactive Protein Transgenic Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 2094-2099.	1.1	30
58	No Effect of C-Reactive Protein on Early Atherosclerosis Development in Apolipoprotein E*3-Leiden/Human C-Reactive Protein Transgenic Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 1635-1640.	1.1	115
59	Effect of Low Dose Atorvastatin Versus Diet-Induced Cholesterol Lowering on Atherosclerotic Lesion Progression and Inflammation in Apolipoprotein E*3-Leiden Transgenic Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, 161-167.	1.1	77
60	C3a expressed in the central nervous system protects against LPS-induced shock. <i>Neuroscience Letters</i> , 2005, 387, 68-71.	1.0	49
61	C-Reactive Protein Accelerates the Progression of Atherosclerosis in Apolipoprotein E-deficient Mice. <i>Circulation</i> , 2004, 109, 647-655.	1.6	371
62	Effects of PspA and Antibodies to PspA on Activation and Deposition of Complement on the Pneumococcal Surface. <i>Infection and Immunity</i> , 2004, 72, 114-122.	1.0	156
63	C-Reactive Protein (CRP) and Autoimmune Disease: Facts and Conjectures. <i>Clinical and Developmental Immunology</i> , 2004, 11, 221-226.	3.3	65
64	The Virulence Function of <i>Streptococcus pneumoniae</i> Surface Protein A Involves Inhibition of Complement Activation and Impairment of Complement Receptor-Mediated Protection. <i>Journal of Immunology</i> , 2004, 173, 7506-7512.	0.4	102
65	Bioluminescence imaging reveals a significant role for complement in liver transduction following intravenous delivery of adenovirus. <i>Gene Therapy</i> , 2004, 11, 1482-1486.	2.3	39
66	Fc receptors and the common γ -chain in experimental autoimmune encephalomyelitis. <i>Journal of Neuroscience Research</i> , 2004, 75, 597-602.	1.3	13
67	Evidence for anti-inflammatory activity of statins and PPAR α activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro. <i>Blood</i> , 2004, 103, 4188-4194.	0.6	166
68	Delayed lupus onset in (NZB \times NZW)F1 mice expressing a human C-reactive protein transgene. <i>Arthritis and Rheumatism</i> , 2003, 48, 1602-1611.	6.7	90
69	Both Family 1 and Family 2 PspA Proteins Can Inhibit Complement Deposition and Confer Virulence to a Capsular Serotype 3 Strain of <i>Streptococcus pneumoniae</i> . <i>Infection and Immunity</i> , 2003, 71, 75-85.	1.0	122
70	Increased Thrombosis After Arterial Injury in Human C-Reactive Protein Transgenic Mice. <i>Circulation</i> , 2003, 108, 512-515.	1.6	268
71	Fc γ Rs Modulate Cytotoxicity of Anti-Fas Antibodies: Implications for Agonistic Antibody-Based Therapeutics. <i>Journal of Immunology</i> , 2003, 171, 562-568.	0.4	96
72	Experimental Allergic Encephalomyelitis Is Inhibited in Transgenic Mice Expressing Human C-Reactive Protein. <i>Journal of Immunology</i> , 2002, 168, 5792-5797.	0.4	84

#	ARTICLE	IF	CITATIONS
73	The biological functions of C-reactive protein. <i>Vascular Pharmacology</i> , 2002, 39, 105-107.	1.0	52
74	The antimicrobial activity of C-reactive protein. <i>Microbes and Infection</i> , 2002, 4, 201-205.	1.0	84
75	Association between baseline levels of C-reactive protein (CRP) and a dinucleotide repeat polymorphism in the intron of the CRP gene. <i>Genes and Immunity</i> , 2002, 3, 14-19.	2.2	131
76	Varied Biologic Functions of C-reactive Protein: Lessons Learned from Transgenic Mice. <i>Immunologic Research</i> , 2002, 26, 279-288.	1.3	72
77	The Arthus Reaction in Rodents: Species-Specific Requirement of Complement. <i>Journal of Immunology</i> , 2000, 164, 463-468.	0.4	54
78	Human C-Reactive Protein Is Protective against Fatal <i>Salmonella enterica</i> Serovar Typhimurium Infection in Transgenic Mice. <i>Infection and Immunity</i> , 2000, 68, 5652-5656.	1.0	107
79	Complement-Dependent Acute-Phase Expression of C-Reactive Protein and Serum Amyloid P-Component. <i>Journal of Immunology</i> , 2000, 165, 1030-1035.	0.4	79
80	Attenuation of Experimental Autoimmune Demyelination in Complement-Deficient Mice. <i>Journal of Immunology</i> , 2000, 165, 5867-5873.	0.4	120
81	C-reactive Protein: A Physiological Activator of Interleukin 6 Receptor Shedding. <i>Journal of Experimental Medicine</i> , 1999, 189, 599-604.	4.2	161
82	C-Reactive Protein: Structural Biology and Host Defense Function. <i>Clinical Chemistry and Laboratory Medicine</i> , 1999, 37, 265-70.	1.4	80
83	Genetic disruption of the murine complement C3 promoter region generates deficient mice with extrahepatic expression of C3 mRNA. <i>Immunopharmacology</i> , 1999, 42, 135-149.	2.0	159
84	Tumor Necrosis Factor Alpha Receptor I Is Important for Survival from <i>Streptococcus pneumoniae</i> Infections. <i>Infection and Immunity</i> , 1999, 67, 595-601.	1.0	78
85	Pneumococcal Surface Protein A Inhibits Complement Activation by <i>Streptococcus pneumoniae</i> . <i>Infection and Immunity</i> , 1999, 67, 4720-4724.	1.0	243
86	Serum anti-LPS antibody production by rainbow trout (<i>Oncorhynchus mykiss</i>) in response to the administration of free and liposomally-incorporated LPS from <i>Aeromonas salmonicida</i> . <i>Fish and Shellfish Immunology</i> , 1997, 7, 387-401.	1.6	20
87	An Alternative Procedure for Isolation of Rainbow Trout, <i>Oncorhynchus mykiss</i> , Serum Immunoglobulin. <i>Journal of Applied Aquaculture</i> , 1996, 5, 33-45.	0.7	0
88	Changes in serum concentrations of channel catfish (<i>Ictalurus punctatus</i> Rafinesque) phosphorylcholine-reactive protein (PRP) in response to inflammatory agents, low temperature-shock and infection by the fungus <i>Saprolegnia</i> sp.. <i>Fish and Shellfish Immunology</i> , 1994, 4, 323-336.	1.6	40
89	Uptake and biodistribution of free and liposomally incorporated lipopolysaccharide of <i>aeromonas salmonicida</i> administered via different routes to rainbow trout: (<i>Oncorhynchus mykiss</i>). <i>Journal of Liposome Research</i> , 1994, 4, 1029-1048.	1.5	8
90	Environmental factors affecting outbreaks of winter saprolegniosis in channel catfish, <i>Ictalurus punctatus</i> (Rafinesque). <i>Journal of Fish Diseases</i> , 1993, 16, 541-549.	0.9	53

#	ARTICLE	IF	CITATIONS
91	Isolation of an acute-phase phosphorylcholine-reactive pentraxin from channel catfish (<i>Ictalurus</i>) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 6 535-543.	0.2	29
92	Chelation affects the conformation, lability and aggregation of channel catfish (<i>Ictalurus punctatus</i>) phosphorylcholine-reactive protein (PRP). Comparative Biochemistry and Physiology Part B: Comparative Biochemistry, 1992, 102, 545-550.	0.2	3
93	Role of Predation and Parasitism in Growth and Mortality of Yellow Perch in Dauphin Lake, Manitoba. Transactions of the American Fisheries Society, 1991, 120, 739-751.	0.6	25
94	Genetic and morphological variability in a population of <i>Diphyllobothrium dendriticum</i> (Nitzsch,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 6	0.5	11
95	<i>Proteocephalus ambloplitis</i> and <i>Contracaecum</i> sp. from Largemouth Bass (<i>Micropterus salmoides</i>) Stocked into Boundary Reservoir, Saskatchewan. Journal of Parasitology, 1990, 76, 598.	0.3	6
96	Differences in numbers and inequalities in mass and fecundity during the egg-producing period for <i>Raphidascaris acus</i> (Nematoda: Anisakidae). Parasitology, 1989, 98, 489-495.	0.7	43
97	HELMINTHS OF STOCKED RAINBOW TROUT (<i>SALMO GAIRDNERI</i>) WITH SPECIAL REFERENCE TO <i>CLINOSTOMUM COMPLANATUM</i> . Journal of Wildlife Diseases, 1988, 24, 456-460.	0.3	9
98	Morphological variability in <i>Echinorhynchus gadi</i> , <i>E. leidy</i> , and <i>E. salmonis</i> (Acanthocephala: Echinorhynchidae) from fishes in northern Canadian waters. Canadian Journal of Zoology, 1986, 64, 985-995.	0.4	26